RESOURCES

• Antibody specificity against highly conserved membrane protein Claudin 6 driven by single atomic contact point Screnci et al. 2022 iScience 25, 105665

• Structure and mechanism of blood– brain-barrier lipid transporter MFSD2A Wood et al. 2021 Nature 596, 444-448

• Generating therapeutic monoclonal antibodies to complex multi-spanning membrane targets: Overcoming the antigen challenge and enabling discovery strategies Dodd et al. 2020 Methods 180, 111-126

• Ion channels as therapeutic antibody targets Hutchings et al. 2019 mAbs 11, 265-296

• Isolation of state-dependent monoclonal antibodies against the 12-transmembrane domain glucose transporter 4 using virus-like particles Tucker et al. 2018 Proceedings of the National Academy of Sciences of the United States of America 115, 4990-4999

• The Bitter Taste Receptor TAS2R16 Achieves High Specificity and Accommodates Diverse Glycoside Ligands by using a Two-faced Binding Pocket Thomas et al. 2017 Scientific Reports 7, 7753-7768

• Discovery of functional mAbs targeting GPCRs and ion channels Wilkinson. 2016 Biochemical Society Transactions 44, 831-837

• Signal transmission through the CXC chemokine receptor 4 (CXCR4) transmembrane helices Wescott et al. 2016 Proceedings of the National Academy of Sciences of the United States of America 113, 9928-9933

• Optimizing Membrane Protein Expression: Improving Surface Expression and Stability for Antibody and Vaccine Discovery Doranz et al. 2015 Genetic Engineering News 35, 15

• A functional comparison of the domestic cat bitter receptors Tas2r38 and Tas2r43 with their human orthologs Sandau et al. 2015 BMC Neuroscience 16, 1-11

• Antibody specificity against highly conserved membrane protein claudin 6 driven by single atomic contact point Screnci et al. 2022 iScience 25, 105665

• Structure and mechanism of blood– brain-barrier lipid transporter MFSD2A Wood et al. 2021 Nature 596, 444-448

• D-dopachrome tautomerase contributes to lung epithelial repair via atypical chemokine receptor 3-dependent Akt signaling Song et al. 2021 EBioMedicine 68, 103412

• VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis Low et al. 2020 mAbs 12, 1709322

• Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4 Griffiths et al. 2019 mAbs 11, 1331-1340

• Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates Costa et al. 2019 Scientific Reports 9, 2443

• CXCR4-targeting nanobodies differentially inhibit CXCR4 function and HIV entry Van Hout et al. 2018 Biochemical Pharmacology 158, 402-412

• Isolation of state-dependent monoclonal antibodies against the 12-transmembrane domain glucose transporter 4 using virus-like particles Tucker et al. 2018 Proceedings of the National Academy of Sciences of the United States of America 115, 4990-4999

• The constituitive activity of the virally encoded chemokine receptor US28 accelerates glioblastoma growth Heukers et al. 2018 Oncogene 37, 4110-4121

• Anti-fibrotic Effects of CXCR4-Targeting i-body AD-114 in Preclinical Models of Pulmonary Fibrosis Griffiths et al. 2018 Scientific Reports 8, 3212

• DNA immunization combined with scFv phage display identifies antagonistic GCGR specific antibodies and reveals new epitopes on the small extracellular loops Van der Woning et al. 2016 mAbs 8, 1126–1135

• Systematic analysis of human antibody response to ebolavirus glycoprotein shows high prevalence of neutralizing public clonotypes Chen et al. 2023 Cell Reports 42, 112370

• Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity Chen et al. 2023 Nature Communications 14, 580

• AL008 enhances myeloid antitumor function by inhibiting SIRPa signaling and activating Fc receptors Yang et al. 2023 Journal of Immunology 210, 204-215

• Antibody specificity against highly conserved membrane protein claudin 6 driven by single atomic contact point Screnci et al. 2022 iScience 25, 105665

• Broadly neutralizing antibodies target the coronavirus fusion peptide Dacon et al. 2022 Science 377, 728-735

• Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein Suryadevara et al. 2021 Cell 184, 2316-2331

• Functional convergence of a germline-encoded neutralizing antibody response in rhesus macaques immunized with HCV envelope glycoproteins Chen et al. 2021 Immunity 54, 781-796

• Pan-protective anti-alphavirus human antibodies target a conserved E1 protein epitope Kim et al. 2021 Cell 184, 4414-4429

• A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via contextdependent T cell costimulation and checkpoint blockade Geuijen et al. 2021 Nature Communications 12, 4445

• Analysis of a therapeutic antibody cocktail reveals determinants for cooperative and broad ebolavirus neutralization Gilchuk et al. 2020 Immunity 52, 388-403

• Potent ZIKV and DENV cross-neutralizing antibodies induced by Zika vaccination in a DENV-experienced donor Dussupt et al. 2020 Nature Medicine 26, 228-235

• Brain-specific angiogenesis inhibitor 1 is expressed in the Myo/Nog cell lineage Gerhart et al. 2020 PLoS One 15, e0234792

• A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes Davidson and Doranz. 2014 Immunology 143, 13-20

Additional publications by Integral Molecular

• Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses Dacon et al. 2022 Cell Host & Microbe

• Therapeutic alphavirus cross-reactive E1 human antibodies inhibit viral egress Williamson et al. 2021 Cell 184, 4430-3336

• Somatic Hypermutation and Framework Mutations of Variable Region Contribute to Anti-Zika Virus-Specific Monoclonal Antibody Binding and Function Tsuji et al. 2022 Journal of Virology 96, e00071-22

• Sites of vulnerability in HCV E1E2 identified by comprehensive functional screening Pfaff-Kilgore et al. 2022 Cell Reports 39, 110859

• An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer Suryadevara et al. 2022 Journal of Clinical Investigation 132, e159062

• Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries Yuan et al. 2022 mAbs 14, e2002236

• Exposing cryptic epitopes on the Venezuelan equine encephalitis virus E1 glycoprotein prior to treatment with alphavirus cross-reactive monoclonal antibody allows blockage of replication early in infection Calvert et al. 2022 Virology 565, 13-21

• Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape Ku et al. 2021 Nature Communications 12, 469

• Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals Chen et al. 2021 Cell Reports 36, 109604

• Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition Kramer et al. 2021 Cell Reports 5, 109784

• Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations Dussupt et al. 2021 Nature Immunology 22, 1503-1514

• Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma Gilchuk et al. 2021 Frontiers in Immunology 12, 706757

• An affinity-matured human monoclonal antibody targeting fusion loop epitope of dengue virus with in vivo therapeutic potency Kotaki et al. 2021 Scientific Reports 11, 12987

• A Novel Antigenic Site Spanning Domains I and III of the Zika Virus Envelope Glycoprotein Is the Target of Strongly Neutralizing Human Monoclonal Antibodies Graham et al. 2021 Journal of Virology 95, e02423

• Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies Murin et al. 2021 Cell Reports 35, 108984

• Integrated pipeline for the accelerated discovery of antiviral antibody therapeutics Gilchuk et al. 2020 Nature Biomedical Engineering 4, 1030-1043

• Transcriptional and clonal characterization of B cell plasmablast diversity following primary and secondary natural DENV infection Waickman et al. 2020 EBioMedicine 54, 102733

• Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other Antibodies Ilinykh et al. 2020 Cell Host & Microbe 27, 976-991

• Convalescent patient-derived monoclonal antibodies targeting different epitopes of E protein confer protection against Zika virus in a neonatal mouse model Niu et al. 2019 Emerging Microbes & Infections 8, 749-759

• Human antibody response to Zika targets type-specific quaternary structure epitopes Collins et al. 2019 JCI Insight 4, E124588

• Potent neutralizing antibodies elicited by dengue vaccine in rhesus macaque target diverse epitopes Li et al. 2019 PLoS Pathogens 15, E1007716

• Broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics Durham et al. 2019 eLife 8, e52384

• Monoclonal antibody 2C6 targets cross-clade conformational epitope in GP41 with highly active antibody dependent cell cytotoxicity Sojar et al. 2019 Journal of Virology 93, e00772

• Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2 Colbert et al. 2019 Journal of Virology 93, e02070

• Early human B cell response to Ebola virus in four U.S. survivors of infection Williamson et al. 2019 Journal of Virology 93, e01439

• Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-FcγR interaction on monocytes Fox et al. 2019 Science Immunology 4, eaav5062

• Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitope Long et al. 2019 Proceedings of the National Academy of Sciences of the United States of America 116, 1591-1596

• Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth Chukwuma et al. 2018 PLoS One 13, E0209437

• Broadly neutralizing antibody mediated clearance of human hepatitis C virus infection Kinchen et al. 2018 Cell Host & Microbe 24, 717-730

• In vivo delivery of synthetic human DNA-encoded monoclonal antibodies protect against ebolavirus infection in a mouse model Patel et al. 2018 Cell Reports 25, 1982-1993

• Systematic analysis of monoclonal antibodies against Ebola virus GP defines features that contribute to protection Saphire et al. 2018 Cell 174, 938-952

• Multifunctional pan-ebolavirus antibody recognizes a site of broad vulnerability on the ebolavirus glycoprotein Gilchuk et al. 2018 Immunity 49, 363-374

• Mxra8 is a receptor for multiple arthritogenic alphaviruses Zhang et al. 2018 Nature 557, 570-574

• Human antibody recognition of antigenic site IV on Pneumovirus fusion proteins Mousa et al. 2018 PLoS Pathogens 14, e1006837

• Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2–MPER region Flyak et al. Nature Microbiology 3, 670-677

• High-throughput Protein Engineering Improves the Antigenicity and Stability of Soluble HIV-1 Envelope Glycoprotein SOSIP Trimers Sullivan et al. 2017 Journal of Virology 91, E00862

• Probing the antigenicity of hepatitis C virus envelope glycoprotein complex by high-throughput mutagenesis Gopal et al. 2017 PLoS Pathogens 13, E1006735

• Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability Zhao et al. 2017 Cell 169, 891-904

• Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus Howell et al. 2017 Cell Reports 19, 413-424

• Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance Bailey et al. 2017 JCI Insights 2, E92872

• A Biologically-validated HCV E1E2 Heterodimer Structural Model Castelli et al. 2017 Scientific Reports 7, 214-227

• Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination Nivarthi et al. 2017 Journal of Virology 91, E02041

• How to turn competitors into collaborators Saphire at al. 2017 Nature 541, 283-285

• Neutralizing Monoclonal Antibodies Block Chikungunya Virus Entry and Release by Targeting an Epitope Critical to Viral Pathogenesis Jin et al. 2016 Cell Reports 13, 2553-2564

• Protective Capacity of the Human Anamnestic Antibody Response during Acute Dengue Virus Infection Xu et al. 2016 Journal of Virology 90, 11122-11131

• Rapid isolation of dengue-neutralizing antibodies from single cell-sorted human antigen-specific memory B-cell cultures Cox et al. 2016 mAbs 8, 129-140

• Integral Molecular Sizes Up Ebola: Membrane Protein Specialist Maps Ebola’s Binding Sites to Advance Vaccine Discovery Dutton. 2016 Genetic Engineering News 36, 1

• Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein Mousa et al. 2016 Proceedings of the National Academy of Sciences of the United States of America 113, E6849–E6858

• Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice Sapparapu et al. 2016 Nature 540, 443–447

• Human Antibodies that Recognize Novel Immunodominant Quaternary Epitopes on the HIV-1 Env Protein Hicar et al. 2016 PLoS One 11, E0158861

• Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site Smith et al. 2016 Journal of Virology 90, 780-789

• Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site Howell et al. 2016 Cell Reports 15, 1514-26

• Lower IgG somatic hypermutation rates during acute dengue virus infection is compatible with a germinal center-independent B cell response Godoy-Lozano et al. 2016 Genome Medicine 8, 23

• Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection Flyak et al. 2016 Cell 164, 392-405

• Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies Davidson et al. 2015 Journal of Virology 89, 10982-10992

• Cryo-EM structures Elucidate Neutralizing Mechanisms of anti-Chikungunya Human Monoclonal Antibodies with Therapeutic Activity Long et al. 2015 Proceedings of the National Academy of Sciences of the United States of America 112, 13898-13903

• Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells Oh et al. 2023 Nature Biotechnology

• The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity Zhang et al. 2022 Scientific Reports 12, 10488

• A humanized nanobody phage display library yields potent binders of SARS-CoV-2 spike Fu et al. 2022 PLoS One 17, e0272364

• Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma Qu et al. 2022 Journal of Immunotherapy for Cancer 10, e005145

• A highly-specific fully-human antibody and CAR-T cells targeting CD66e/CEACAM5 are cytotoxic for CD66e-expressing cancer cells in vitro and in vivo Baek et al. 2022 Cancer Letters 525, 97-107

• GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity Heitzeneder et al. 2022 Cancer Cell 40, 53-69

• Testing for Off-target Binding Norden and Doranz. 2021 Translational Medicine: Optimizing Preclinical Safety Evaluation of Biopharmaceuticals

• A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL Tan et al. 2021 Blood Cancer Journal 11, 71

• Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4 Bhoj et al. 2021 Molecular Therapy Oncolytics 20, 387-398

• Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris Lee et al. 2020 Journal of Clinical Investigation 130, 6317-6324

• High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models Li et al. 2020 Cell 183, 429-441

• CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide Radhakrishnan et al. 2020 Nature Communications 11, 798

• Screening the Membrane Proteome- A High-Throughput Platform for Identifying Membrane Protein Antibody Targets Huston-Paterson et al. 2016 Genetic Engineering News 36, 15

• Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model Kalnin et al. 2022 Vaccine 40, 1289-1298

• IMM-BCP-01, a patient-derived anti-SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2 Nikitin et al. 2022 Science Immunology 7, eabl9943

• Hexamerization of Anti-SARS CoV IgG1 Antibodies Improves Neutralization Capacity Pande et al. 2022 Frontiers in Immunology 13, 864775

• Robust validation and performance comparison of immunogenicity assays assessing IgG and neutralizing antibodies to SARS-CoV-2 Bonhomme et al. 2022 PLoS One 17, e0262922

• A high throughput reporter virus particle microneutralization assay for quantitation of Zika virus neutralizing antibodies in multiple species Bohning et al. 2021 PLoS One 16, e0250516

• SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity Trinite et al. 2021 Scientific Reports 11, 2608

• Single dose of chimeric dengue-2/Zika vaccine candidate protects mice and non-human primates against Zika virus Baldwin et al. 2021 Nature Communications 12, 7320

• Prolonged evolution of the human B cell response to SARS-CoV-2 infection Sakharkar et al. 2021 Science Immunology 6, eabg6916

• Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes Sun et al. 2021 Nature Communications 12, 4676

• Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2 Xiang et al. 2020 Science 370, 1479-1484

• Antigenicity, stability, and reproducibility of Zika reporter virus particles for long-term applications Whitbeck et al. 2020 PLoS Neglected Tropical Diseases 14, e0008730

• Complete Protection in Macaques Conferred by Purified Inactivated Zika Vaccine: Defining a Correlate of Protection Young et al. 2020 Scientific Reports 10, 3488